Inhibrx Biosciences, Inc. INBX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $161.66M-25.3% | $124.22M-18.6% | $153.09M-22.0% | $186.57M-17.8% | $216.52M-14.2% | ||
| $9.5M+42.8% | $8.44M+14.3% | $7.5M-24.9% | $6.43M-53.4% | $6.65M+182% | ||
| $171.34M-23.3% | $132.83M-17.2% | $161.42M-22.2% | $193.96M-19.9% | $223.39M— | ||
| $3.2M-42.4% | $3.73M-39.8% | $4.31M-37.4% | $4.89M-35.8% | $5.55M— | ||
| $11.66M+21.8% | $11.12M+25.1% | $10.58M+28.7% | $10.23M+36.8% | $9.57M— | ||
| 10.2%0.0% | 10.2%-733,799,990% | 10.2%+2.0% | 10.2%+2.0% | 10.2%— | ||
| $4.38M-35.6% | $4.38M-35.9% | $5.74M-14.5% | $6.81M+0.9% | $6.8M— | ||
| $183.97M-24.2% | $146.48M-19.0% | $177.47M-20.3% | $212.12M-17.9% | $242.64M— | ||
| $8.76M-1.5% | $5.94M-35.7% | $6.77M-45.2% | $8.29M-36.3% | $8.89M+120% | ||
| $2.24M-17.5% | $7.45M-75.1% | $4.84M-25.2% | $3.85M-14.6% | $2.72M— | ||
| $2.41M+22.0% | $2.33M+45.8% | $2.25M+22.5% | $2.17M-0.1% | $1.97M— | ||
| $26.51M-39.2% | $33.8M-17.0% | $35.98M-18.4% | $38.94M-0.3% | $43.64M— | ||
| $174.99M+77.4% | $100.56M— | $99.92M— | $99.28M— | $98.65M— | ||
| $3.5M-40.8% | $4.13M-36.0% | $4.74M— | $5.34M— | $5.9M— | ||
| $5.9M-25.0% | $6.45M-19.8% | $6.99M+281% | $7.51M+246% | $7.88M— | ||
| $205M+38.3% | $138.49M+194% | $140.64M+219% | $143.56M+268% | $148.2M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| 120M0.0% | 120M+11,999,900% | 120M0.0% | 120M0.0% | 120M— | ||
| $258.59M+6.0% | $254.18M+6.0% | $250.18M+5.7% | $246.66M+5.5% | $243.89M— | ||
| -$279.63M-87.1% | -$246.19M-132% | -$213.35M-266% | -$178.1M-1,137% | -$149.44M— | ||
| -$21.04M-122% | $7.99M-94.0% | $36.83M-79.4% | $68.56M-68.7% | $94.44M+716% | ||
| $183.97M-24.2% | $146.48M-19.0% | $177.47M-20.3% | $212.12M-17.9% | $242.64M— | ||
| $262K-2.6% | $238K-37.7% | $410K-45.2% | $283K-70.7% | $269K— | ||
| $186K— | $177K-10.2% | $727K— | $730K-23.3% | —— | ||
| $186K— | $177K-10.2% | $727K— | $730K-23.3% | —— | ||
| $4.38M-35.6% | $4.38M-35.9% | $5.74M-14.5% | $6.81M+0.9% | $6.8M— | ||
| $5.05M-26.8% | $5.54M-24.6% | $6M+294% | $6.46M+221% | $6.9M— | ||
| $5.05M-26.8% | $5.54M-24.6% | $6M+294% | $6.46M+221% | $6.9M— | ||
| $4.38M-35.6% | $4.38M-35.9% | $5.74M-14.5% | $6.81M+0.9% | $6.8M— | ||
| $14.85M-1.7% | $14.85M-1.6% | $14.88M-1.4% | $15.11M+0.2% | $15.11M— | ||
| $5.05M-26.8% | $5.54M-24.6% | $6M+294% | $6.46M+221% | $6.9M— | ||
| $4.38M-35.6% | $4.38M-35.9% | $5.74M-14.5% | $6.81M+0.9% | $6.8M— | ||
| $2.24M-17.5% | $7.45M-3.6% | $4.84M-25.2% | $3.85M-14.6% | $2.72M— | ||
| $15.34M-53.2% | $25.53M-14.6% | $26.96M-9.8% | $28.48M+19.4% | $32.77M— | ||
| $15.34M-53.2% | $25.53M-14.6% | $26.96M-9.8% | $28.48M+19.4% | $32.77M— | ||
| $2.24M-17.5% | $7.45M-3.6% | $4.84M-25.2% | $3.85M-14.6% | $2.72M— | ||
| $2.15M+9.4% | —— | $703K-6.9% | $1.41M+24.3% | $1.97M— | ||
| $1.49M-49.3% | —— | $2.94M+159% | $2.94M+159% | $2.94M— | ||
| $1.49M-49.3% | —— | $2.94M+159% | $2.94M+159% | $2.94M— | ||
| $1.49M-49.3% | —— | $2.94M— | $2.94M— | $2.94M— | ||
| $2.94M+3.0% | —— | $2.86M+151% | $2.86M+151% | $2.86M— | ||
| $6.59M-28.8% | —— | $7.99M+322% | $8.7M+283% | $9.26M— | ||
| $681K-50.6% | —— | $1M+1,660% | $1.19M+1,109% | $1.38M— | ||
| $591K-3.7% | $447K-28.9% | $598K-68.2% | $1.07M+12.0% | $614K— | ||
| $1.49M0.0% | —— | $1.49M— | $1.49M— | $1.49M— | ||
| $180.9M+69.8% | $107.01M+1,230% | $106.91M+5,726% | $106.79M+4,819% | $106.53M— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.00— | ||
| 14.6M+0.9% | 14.6M+0.7% | 14.5M+0.2% | 14.5M+8.7% | 14.5M— | ||
| 15M0.0% | 15M0.0% | 15M0.0% | 15M0.0% | 15M— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.00— | ||
| 5M-2.1% | 5.1M+2.8% | 5.1M+2.4% | 5.1M+2.8% | 5.1M— | ||
| $14.85M-1.7% | $14.85M-1.6% | $14.88M— | $15.11M— | $15.11M— | ||
| $2.14M-75.3% | $5.54M-1.8% | $5.91M+363% | $8.44M+86.0% | $8.68M— | ||
| $8.58M-54.6% | $10.79M-27.0% | $14.2M-4.4% | $13.13M+7.5% | $18.9M— | ||
| $857K0.0% | $857K— | —— | —— | $857K— | ||
| $236K-62.1% | $111K-82.4% | $286K-94.3% | $771K-36.6% | $622K— | ||
| $591K-3.7% | $447K-28.9% | $598K-68.2% | $1.07M+12.0% | $614K— | ||
| $1.56M-17.6% | $1.88M-5.9% | $2.25M-26.3% | $2.48M-49.7% | $1.89M— | ||
| $5.79M+300% | $4.57M+28.8% | $2.82M-36.5% | $1.68M-71.5% | $1.45M— | ||
| $5.02M-2.1% | $5.13M+2.8% | $5.11M+2.4% | $5.13M+2.8% | $5.13M— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $0— | ||
| $120M0.0% | $120M0.0% | $120M0.0% | $120M0.0% | $120M— | ||
| $14.61M+0.9% | $14.58M+0.7% | $14.5M+0.2% | $14.48M+8.7% | $14.48M— | ||
| $14.61M+0.9% | $14.58M+0.7% | $14.5M+0.2% | $14.48M0.0% | $14.48M— | ||
| $6.59M-28.8% | —— | $7.99M+322% | $8.7M+283% | $9.26M— | ||
| $681K-50.6% | —— | $1M+1,660% | $1.19M+1,109% | $1.38M— | ||
| $0.10.0% | $0.10.0% | $0.1+24.4% | $0.1+24.4% | $0.1— | ||
| $693K+82.4% | $328K-29.5% | $300K-16.2% | $387K-8.5% | $380K— | ||
| $506K-58.6% | $448K-30.2% | $736K+12.0% | $766K-13.6% | $1.22M— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $0— | ||
| $15M0.0% | $15M0.0% | $15M0.0% | $15M0.0% | $15M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $1.39M-24.0% | $1.3M+59.7% | $1.29M— | $1.22M— | $1.82M— | ||
| $2.15M+9.4% | —— | $703K-6.9% | $1.41M+24.3% | $1.97M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Inhibrx Biosciences, Inc.'s total assets?
- Inhibrx Biosciences, Inc. (INBX) holds $184.0M in total assets, down 24.2% year over year.
- How much debt does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. carries $180.9M in total debt against -$21.0M of shareholders' equity, a debt-to-equity ratio of 13.39.
- How much cash does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. holds $161.7M in cash and equivalents.
- Can Inhibrx Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 6.46 — current assets exceed current liabilities.
- Where does Inhibrx Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
